SMHSMH·1hBusiness
score-0.30
CSL's $10 billion write-down: A home-grown giant weighs path to redemption
Original
Changing fortunes: is Biotech giant CSL’s $10 billion write-down a comeback story?
“Highlights significant financial loss and long-term decline while speculating on a potential, unproven recovery path.”